Home > Journals > Minerva Orthopedics > Past Issues > Minerva Ortopedica e Traumatologica 2020 December;71(4) > Minerva Ortopedica e Traumatologica 2020 December;71(4):151-9

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Ortopedica e Traumatologica 2020 December;71(4):151-9

DOI: 10.23736/S0394-3410.20.04012-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

New opportunities for the management of gonarthrosis: an observational study

Giovanni B. VAVALLE, Francesco FORTUNATO

Unit of Orthopedics, Santa Maria GVM Care and Research Hospital, Bari, Italy



BACKGROUND: Gonarthrosis, a common form of degenerative osteoarthritis (OA), is characterized by inflammation, pain and limitation of movement. Currently, nonsteroidal anti-inflammatory drugs, analgesics and steroids are the only symptom-modifying agents approved as OA interventions, but their consistent side effects limit their use. Recently, clinical trials have been performed to evaluate whether some dietary supplements can be used for a long-term period without side effects. This work presents an observational study comparing the dietary supplement Flexart® Flogo and a glucosamine sulphate therapy for the treatment of OA, with the aim to verify whether Flexart® Flogo could be considered a promising therapeutic option.
METHODS: Patients between 50 and 70 years old with a diagnosis of stage I or II gonarthrosis were included in the study and evaluated for 90 days, for both treatments. A Visual Analogue Scale (VAS) was used for a subjective unidimensional measure of pain intensity. The joint functionality has been evaluated with the Western Ontario and McMaster Universities Arthritis Index (WOMAC).
RESULTS: The use of Flexart® Flogo was associated with a significant reduction of VAS-reported pain score and an improvement in physical function, and overall symptomatology at each follow-up, compared to treatment with glucosamine sulphate. In particular, the improvement of joint functionality has been observed in patients with severe pain at baseline.
CONCLUSIONS: The treatment with Flexart® Flogo promotes the relief from OA symptoms, avoiding adverse effects of conventional pharmacological treatments. Consequently, it can be considered a safe and effective treatment for OA patients.


KEY WORDS: Osteoarthritis; Dietary supplements; Visual Analog Scale

top of page